دورية أكاديمية
أعرض في EDS

Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein.

التفاصيل البيبلوغرافية
العنوان: Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein.
المؤلفون: Lechuga GC; Center for Technological Development in Health (CDTS), National Institute of Science and Technology for Innovation in Neglected Population Diseases (INCT-IDPN), Oswald Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil.; Cellular Ultrastructure Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil., Temerozo JR; Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.; National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil., Napoleão-Pêgo P; Center for Technological Development in Health (CDTS), National Institute of Science and Technology for Innovation in Neglected Population Diseases (INCT-IDPN), Oswald Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil., Carvalho JPRS; Center for Technological Development in Health (CDTS), National Institute of Science and Technology for Innovation in Neglected Population Diseases (INCT-IDPN), Oswald Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil.; Graduate Program in Science and Biotechnology, Department of Molecular and Cellular Biology, Biology Institute, Fluminense Federal University, Niterói 24220-900, Brazil., Gomes LR; Center for Technological Development in Health (CDTS), National Institute of Science and Technology for Innovation in Neglected Population Diseases (INCT-IDPN), Oswald Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil., Bou-Habib DC; Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.; National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil., Morel CM; Center for Technological Development in Health (CDTS), National Institute of Science and Technology for Innovation in Neglected Population Diseases (INCT-IDPN), Oswald Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil., Provance DW Jr; Center for Technological Development in Health (CDTS), National Institute of Science and Technology for Innovation in Neglected Population Diseases (INCT-IDPN), Oswald Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil., Souza TML; Center for Technological Development in Health (CDTS), National Institute of Science and Technology for Innovation in Neglected Population Diseases (INCT-IDPN), Oswald Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil.; Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil., De-Simone SG; Center for Technological Development in Health (CDTS), National Institute of Science and Technology for Innovation in Neglected Population Diseases (INCT-IDPN), Oswald Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil.; Graduate Program in Science and Biotechnology, Department of Molecular and Cellular Biology, Biology Institute, Fluminense Federal University, Niterói 24220-900, Brazil.; Epidemiology and Molecular Systematics Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 26; Vol. 25 (15). Date of Electronic Publication: 2024 Jul 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Spike Glycoprotein, Coronavirus*/immunology , Cross Reactions*/immunology , SARS-CoV-2*/immunology , COVID-19*/immunology , COVID-19*/virology , Antibodies, Viral*/immunology , Antibodies, Viral*/blood , Epitopes, B-Lymphocyte*/immunology , Dengue Virus*/immunology, Humans ; Dengue/immunology ; Dengue/virology ; Antibody-Dependent Enhancement/immunology ; Pandemics ; Immunodominant Epitopes/immunology
مستخلص: Despite successful vaccination efforts, the emergence of new SARS-CoV-2 variants poses ongoing challenges to control COVID-19. Understanding humoral responses regarding SARS-CoV-2 infections and their impact is crucial for developing future vaccines that are effective worldwide. Here, we identified 41 immunodominant linear B-cell epitopes in its spike glycoprotein with an SPOT synthesis peptide array probed with a pool of serum from hospitalized COVID-19 patients. The bioinformatics showed a restricted set of epitopes unique to SARS-CoV-2 compared to other coronavirus family members. Potential crosstalk was also detected with Dengue virus (DENV), which was confirmed by screening individuals infected with DENV before the COVID-19 pandemic in a commercial ELISA for anti-SARS-CoV-2 antibodies. A high-resolution evaluation of antibody reactivity against peptides representing epitopes in the spike protein identified ten sequences in the NTD, RBD, and S2 domains. Functionally, antibody-dependent enhancement (ADE) in SARS-CoV-2 infections of monocytes was observed in vitro with pre-pandemic Dengue-positive sera. A significant increase in viral load was measured compared to that of the controls, with no detectable neutralization or considerable cell death, suggesting its role in viral entry. Cross-reactivity against peptides from spike proteins was observed for the pre-pandemic sera. This study highlights the importance of identifying specific epitopes generated during the humoral response to a pathogenic infection to understand the potential interplay of previous and future infections on diseases and their impact on vaccinations and immunodiagnostics.
References: Science. 2020 Nov 27;370(6520):. (PMID: 32994364)
Vaccines (Basel). 2023 Jan 28;11(2):. (PMID: 36851165)
Emerg Microbes Infect. 2022 Dec;11(1):2412-2422. (PMID: 36106670)
Front Immunol. 2022 Dec 01;13:1050478. (PMID: 36532011)
Cell. 2020 Nov 12;183(4):1024-1042.e21. (PMID: 32991844)
Vaccines (Basel). 2021 Mar 26;9(4):. (PMID: 33810325)
Front Immunol. 2021 Nov 19;12:772511. (PMID: 34868035)
Science. 2022 Aug 12;377(6607):735-742. (PMID: 35857703)
Immunol Rev. 2015 Nov;268(1):340-64. (PMID: 26497532)
Nat Rev Immunol. 2023 Mar;23(3):189-199. (PMID: 36168054)
Vaccines (Basel). 2023 Feb 26;11(3):. (PMID: 36992136)
Viruses. 2022 Oct 14;14(10):. (PMID: 36298814)
Cell. 2021 Apr 29;184(9):2372-2383.e9. (PMID: 33743213)
Commun Biol. 2022 Mar 24;5(1):262. (PMID: 35332252)
Science. 2020 Dec 11;370(6522):1339-1343. (PMID: 33159009)
Nature. 2023 Mar;615(7950):143-150. (PMID: 36630998)
Microbiol Spectr. 2022 Apr 27;10(2):e0155321. (PMID: 35319248)
Sci Rep. 2022 Oct 7;12(1):16817. (PMID: 36207326)
Cell. 2021 Aug 5;184(16):4203-4219.e32. (PMID: 34242577)
Cell. 2022 Feb 3;185(3):447-456.e11. (PMID: 35026151)
Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2204256119. (PMID: 35972965)
J Med Virol. 2024 May;96(5):e29628. (PMID: 38682568)
Cell Rep. 2022 Jul 5;40(1):111022. (PMID: 35753310)
Lancet. 2007 Nov 10;370(9599):1644-52. (PMID: 17993365)
Sci Rep. 2021 Jul 28;11(1):15374. (PMID: 34321560)
Nature. 2020 Jul;583(7815):290-295. (PMID: 32422645)
J Virol. 1998 Aug;72(8):6332-8. (PMID: 9658072)
Diagnostics (Basel). 2021 Jun 25;11(7):. (PMID: 34202195)
Cell Host Microbe. 2007 Apr 19;1(2):135-45. (PMID: 18005691)
Nature. 2022 Jun;606(7914):576-584. (PMID: 35385861)
Sci Rep. 2023 Jan 16;13(1):782. (PMID: 36646780)
Sci Immunol. 2021 Jul 29;6(61):. (PMID: 34326184)
Microbiol Spectr. 2021 Oct 31;9(2):e0141621. (PMID: 34704808)
Front Immunol. 2024 Jan 22;15:1328905. (PMID: 38318166)
PLoS Pathog. 2023 Apr 20;19(4):e1010870. (PMID: 37079651)
J Indian Inst Sci. 2022;102(2):671-687. (PMID: 35136306)
Nature. 2020 Aug;584(7821):353-363. (PMID: 32659783)
Intervirology. 2022;65(4):224-229. (PMID: 35134813)
Nat Rev Immunol. 2023 May;23(5):304-316. (PMID: 36539527)
Lancet Microbe. 2020 Jul;1(3):e111-e118. (PMID: 33230504)
J Med Virol. 2020 Aug;92(8):941-955. (PMID: 31784997)
Mol Immunol. 2022 Dec;152:215-223. (PMID: 36379129)
Infect Dis Rep. 2021 Jun 07;13(2):540-551. (PMID: 34200159)
Nanoscale. 2022 Jan 27;14(4):1054-1074. (PMID: 35018939)
Curr HIV Res. 2013 Jul;11(5):421-6. (PMID: 24191936)
Vaccines (Basel). 2023 Nov 24;11(12):. (PMID: 38140154)
Rev Med Virol. 2022 Jul;32(4):e2313. (PMID: 34755408)
Protein Sci. 2021 Jan;30(1):70-82. (PMID: 32881101)
Front Immunol. 2021 Sep 27;12:752003. (PMID: 34646276)
Nat Rev Immunol. 2020 Oct;20(10):615-632. (PMID: 32887954)
Vaccine. 2023 Apr 6;41(15):2427-2429. (PMID: 36906407)
Science. 2021 Sep 03;373(6559):1109-1116. (PMID: 34344823)
Science. 2022 Aug 12;377(6607):728-735. (PMID: 35857439)
Sci Rep. 2021 Jun 11;11(1):12354. (PMID: 34117329)
Commun Biol. 2021 Nov 22;4(1):1317. (PMID: 34811480)
MAbs. 2021 Jan-Dec;13(1):1953683. (PMID: 34313527)
Science. 2017 Nov 17;358(6365):929-932. (PMID: 29097492)
Science. 2022 Apr 22;376(6591):eabn8897. (PMID: 35324257)
Eur J Immunol. 2021 Jul;51(7):1839-1849. (PMID: 33772767)
Front Immunol. 2022 Aug 15;13:941923. (PMID: 36045680)
J Clin Immunol. 2021 Jul;41(5):906-913. (PMID: 33725211)
Rev Med Virol. 2003 Nov-Dec;13(6):387-98. (PMID: 14625886)
Int J Mol Sci. 2023 Jun 28;24(13):. (PMID: 37445984)
Microbiol Spectr. 2022 Dec 21;10(6):e0263922. (PMID: 36445096)
Vaccines (Basel). 2024 Mar 22;12(4):. (PMID: 38675725)
Cell Rep. 2021 Feb 16;34(7):108737. (PMID: 33545052)
Nat Commun. 2022 Aug 18;13(1):4696. (PMID: 35982054)
Viruses. 2022 Sep 14;14(9):. (PMID: 36146847)
JCI Insight. 2021 Apr 22;6(8):. (PMID: 33720905)
N Engl J Med. 2018 Jul 26;379(4):327-340. (PMID: 29897841)
Cell Rep Med. 2021 Jan 19;2(1):100189. (PMID: 33495758)
Sci Rep. 2021 Oct 14;11(1):20383. (PMID: 34650130)
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9422-7. (PMID: 17517625)
Mol Immunol. 2022 Dec;152:172-182. (PMID: 36371813)
Nat Commun. 2020 Mar 27;11(1):1620. (PMID: 32221306)
Viral Immunol. 2003;16(1):69-86. (PMID: 12725690)
Front Med (Lausanne). 2022 Oct 19;9:952697. (PMID: 36341247)
Microorganisms. 2023 Apr 13;11(4):. (PMID: 37110438)
Can J Microbiol. 2021 Oct;67(10):687-702. (PMID: 34171205)
J Med Microbiol. 2021 Jun;70(6):. (PMID: 34110279)
Nature. 2022 Feb;602(7898):676-681. (PMID: 35016198)
Front Cell Infect Microbiol. 2022 Sep 02;12:978440. (PMID: 36118022)
J Virol. 2002 Mar;76(6):2827-34. (PMID: 11861850)
Front Immunol. 2021 Sep 17;12:727989. (PMID: 34603300)
Cell Rep. 2021 Feb 2;34(5):108699. (PMID: 33485405)
Front Immunol. 2022 Oct 18;13:1008285. (PMID: 36330519)
Pathogens. 2023 May 13;12(5):. (PMID: 37242383)
Cytokine. 2020 Dec;136:155256. (PMID: 32866898)
Front Immunol. 2023 May 05;14:1192395. (PMID: 37228598)
معلومات مُعتمدة: #110.198-13 ; #210.003/ 2018 Carlos Chagas Filho Foundation for Research Support of the State of Rio de Ja0neiro/FAPERJ; #467.488/2014-2;#301744/2019-0 Brazilian Council for Scientific Research (CNPq).
فهرسة مساهمة: Keywords: B-cell epitope; COVID-19; Dengue virus; SARS-CoV-2 variants; antibody-mediated enhancement; spike protein; vaccination
المشرفين على المادة: 0 (Spike Glycoprotein, Coronavirus)
0 (spike protein, SARS-CoV-2)
0 (Antibodies, Viral)
0 (Epitopes, B-Lymphocyte)
0 (Immunodominant Epitopes)
تواريخ الأحداث: Date Created: 20240810 Date Completed: 20240810 Latest Revision: 20240812
رمز التحديث: 20240813
مُعرف محوري في PubMed: PMC11311977
DOI: 10.3390/ijms25158180
PMID: 39125749
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25158180